Back to Resource Center

Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)

Adolescent girls and young women (AGYW) in sub-Saharan Africa are disproportionately affected by the HIV epidemic and face an array of challenges using proven behavioral and biomedical prevention methods. To address the urgent need for expanding prevention options, we evaluated the baseline preferences of HIV prevention methods among participants enrolled in the MTN-034/REACH crossover trial along with their stated product preference prior to product initiation. We successfully enrolled African AGYW with a clear unmet need for HIV prevention. The balanced preference between the two products suggests that multiple biomedical prevention options may be appealing to this age group and could address their prevention needs.

June 2023

Click for full info +

Full Info:


Resource Type:

Database
Journal Article
Journal Article
Resource

Citation:

Adolescent girls and young women (AGYW) in sub-Saharan Africa are disproportionately affected by the HIV epidemic and face an array of challenges using proven behavioral and biomedical prevention methods. To address the urgent need for expanding prevention options, we evaluated the baseline preferences of HIV prevention methods among participants enrolled in the MTN-034/REACH crossover trial along with their stated product preference prior to product initiation. We successfully enrolled African AGYW with a clear unmet need for HIV prevention. The balanced preference between the two products suggests that multiple biomedical prevention options may be appealing to this age group and could address their prevention needs.

View Journal Article

Authors: Ngure, K., Friedland, B.A., Szydlo, D.W., Roberts, S.T., Garcia, M., Levy, L., Akello, C.A., Reddy, K., Palanee-Phillips, T., Macdonald, P. and Siziba, B.

Health Risks(s):

  • HIV

Product type(s):

  • HIVinhibitor
  • IVR

Topic(s):

  • Trials
  • Social

Region(s)

  • Africa

Back to Resource Center